- Investing.com
Metrics to compare | ALSEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALSENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.0x | −2.7x | −0.3x | |
PEG Ratio | 0.68 | −0.02 | 0.00 | |
Price/Book | 3.3x | 0.9x | 2.6x | |
Price / LTM Sales | 25.1x | 16.0x | 3.0x | |
Upside (Analyst Target) | 279.1% | 144.9% | 56.7% | |
Fair Value Upside | Unlock | 8.8% | 9.4% | Unlock |
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.